Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

RCT (n=328) found rituximab added to standard lymphomes malins B chemotherapy prolonged event-free survival (93.9 vs. 82.3%, respectively, at 3 years, HR 0.32; 95% CI,0.15-0.66) and was linked to higher incidence of hypogammaglobulinemia and, potentially, more infective episodes


New England Journal of Medicine